Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

Imaging advocates urge feds to fix PET coverage gap following approval of new Alzheimer’s drug

CMS intends to soon propose a new national coverage determination that would loosen restrictions around PET payment, according to a report published Monday. 

Lung cancer cigarettes

Members of Congress introduce bill requiring all Medicaid programs to cover lung cancer screening

H.R. 4286 also would expand coverage for tobacco cessation in the federal payment program, including counseling and medication-assisted treatment. 

Christopher Kit Crancer RBMA

Closing the coverage gap: How to empower patients in mammography

Radiology Business Management Association President Kit Crancer discusses the current coverage landscape for women's imaging and one promising national development. 

brain money alzheimer dementia

Coverage is now available for new Alzheimer's drug

In a July 6 announcement, CMS shared that coverage is officially available for Leqembi for those who meet certain criteria.

Thumbnail

President Biden cracks down on short-term health plans, calls them 'junk insurance'

The proposed rule would require that short-term plans are truly short-term and are active for just three months.

dollar money graph increase finance

Billing claims for nonphysician image interpretation leapt 27% over a 5-year period

"Since several states are shifting toward granting NPPs more autonomy, this is something worth watching," the study's author told Radiology Business

artificial intelligence industry watchers digest

Industry Watcher’s Digest

Buzzworthy developments of the past few days.

Thumbnail

Imaging AI vendors’ marketing hype doesn’t always match materials submitted to the FDA

About 1 in 8 were discovered to have marketing materials that made claims differing from their premarket approval.